- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00404534
Helicobacter Eradication Relief of Dyspeptic Symptoms (HEROES-12)
Dyspeptic Symptoms Evolution After Eradication of Helicobacter Pylori in Patients With Different Endoscopic Findings: a Randomized Double-blind Placebo-controlled Clinical Trial With 12 Months of Follow-up
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective: investigate if a sub-group of functional dyspeptic patients without any use of NSAID or gastric erosions could have a better evolution of their dyspeptic symptoms after Helicobacter eradication than the placebo control group
Design: A randomized double-blind placebo controlled clinical trial
Inclusion Criteria: Patients with more than 18 years, Functional dyspepsia accordingly Rome III criteria, Helicobacter pylori infection by two diagnostic tests
Exclusion Criteria: No concordance with informed consent; Pregnant woman or breast feeding or no trust anticonceptional method; Structural gastrointestinal abnormalities except gastritis, duodenitis or hiatal hernia; Previous treatment for Helicobacter pylori infection; Previous surgery on esophagus, stomach or duodenum; Hypersensitivity to the drugs in study; Proton pump inhibitor use in the previous 15 days; H2-antagonists use in the previous 07 days; Antibiotics use in the previous 30 days; Patients unable to answer the study questionnaires; Alcohol abuse; Drug use; Serious comorbidities; Biliary colic; Irritable bowel syndrome; Gastroesophageal Reflux Disease
Interventions: amoxicillin, clarythromycin, omeprazole for 10 days
Control: Placebo
Outcomes:
Primary: Proportion of patients with 50% reduction of baseline symptoms score measured by the validated Porto Alegre Dyspeptic Symptoms Questionnaire Secondary: Proportion of patients with 100% reduction of baseline symptoms score measured by the validated Porto Alegre Dyspeptic Symptoms Questionnaire; Need of rescue medication; Median difference of score between groups; Mean SF-36 scores evolution between groups; Lost of productivity measured by WPAI between groups
Visits: screening, baseline, 4, 8, 12 months
Endoscopic evaluation: screening, 12 months
Helicobacter detection methods: urease, histology (3 pathologists) performed at screening and 12 months
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-903
- Hospital de Clínicas de Porto Alegre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with more than 18 years
- Functional dyspepsia accordingly Rome III criteria
- Helicobacter pylori infection by two diagnostic tests
Exclusion Criteria:
- No concordance with informed consent
- Pregnant woman or breast feeding or no trust anticonceptional method
- Structural gastrointestinal abnormalities except gastritis, duodenitis or hiatal hernia
- Previous treatment for Helicobacter pylori infection
- Previous surgery on esophagus, stomach or duodenum
- Hypersensitivity to the drugs in study
- Proton pump inhibitor use in the previous 15 days
- H2-antagonists use in the previous 07 days
- Antibiotics use in the previous 30 days
- Patients unable to answer the study questionnaires
- Alcohol abuse
- Drug use
- Serious comorbidities
- Biliary colic
- Irritable bowel syndrome
- Gastroesophageal Reflux Disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
Amoxicillin 1000 mg BID, clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
|
Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator.
Both groups receive omeprazole 20 mg bid for 10 days.
|
PLACEBO_COMPARATOR: 2
Placebo of Amoxicillin 1000 mg BID, placebo of clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
|
Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator.
Both groups receive omeprazole 20 mg bid for 10 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients with 50% reduction of baseline symptoms score measured by the validated Porto Alegre Dyspeptic Symptoms Questionnaire
Time Frame: the last visit among the antecipated visits (4, 8 and 12 months)
|
the last visit among the antecipated visits (4, 8 and 12 months)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patients with 100% reduction of baseline symptoms score measured by the validated Porto Alegre Dyspeptic Symptoms Questionnaire
Time Frame: the last visit among the antecipated visits (4, 8 and 12 months)
|
the last visit among the antecipated visits (4, 8 and 12 months)
|
Need of rescue medication
Time Frame: 4, 8 and 12 months
|
4, 8 and 12 months
|
Median difference of score between groups
Time Frame: the last visit among the antecipated visits (4, 8 and 12 months)
|
the last visit among the antecipated visits (4, 8 and 12 months)
|
Mean SF-36 scores evolution between groups
Time Frame: 12 months
|
12 months
|
Lost of productivity measured by WPAI between groups
Time Frame: 12 months
|
12 months
|
Adverse Events
Time Frame: 4 , 8 and 12 months
|
4 , 8 and 12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Luiz E Mazzoleni, MD, MsC, PhD, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul
- Study Chair: Carlos F Francesconi, MD, PhD, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul
- Study Chair: Guilherme B Sander, MD, MsC, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul
Publications and helpful links
General Publications
- Mazzoleni LE, Sander GB, Ott EA, Barros SG, Francesconi CF, Polanczyk CA, Wortmann AC, Theil AL, Fritscher LG, Rivero LF, Cartell A, Edelweiss MI, Uchoa DM, Prolla JC. Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study. Dig Dis Sci. 2006 Jan;51(1):89-98. doi: 10.1007/s10620-006-3090-6.
- Ott EA, Mazzoleni LE, Edelweiss MI, Sander GB, Wortmann AC, Theil AL, Somm G, Cartell A, Rivero LF, Uchoa DM, Francesconi CF, Prolla JC. Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. Aliment Pharmacol Ther. 2005 May 15;21(10):1231-9. doi: 10.1111/j.1365-2036.2005.02461.x.
- Sander GB, Mazzoleni LE, Francesconi CF, Wortmann AC, Ott EA, Theil A, Da Cruz PV, Da Silva AC, Oliveira L, Beheregaray S, Matioti S, Somm G, Goldim JR. Development and validation of a cross-cultural questionnaire to evaluate nonulcer dyspepsia: the Porto Alegre Dyspeptic Symptoms Questionnaire (PADYQ). Dig Dis Sci. 2004 Nov-Dec;49(11-12):1822-9. doi: 10.1007/s10620-004-9578-z.
- Mazzoleni LE, Sander GB, Francesconi CF, Mazzoleni F, Uchoa DM, De Bona LR, Milbradt TC, Von Reisswitz PS, Berwanger O, Bressel M, Edelweiss MI, Marini SS, Molina CG, Folador L, Lunkes RP, Heck R, Birkhan OA, Spindler BM, Katz N, Colombo Bda S, Guerrieri PP, Renck LB, Grando E, Hocevar de Moura B, Dahmer FD, Rauber J, Prolla JC. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med. 2011 Nov 28;171(21):1929-36. doi: 10.1001/archinternmed.2011.533.
- Sander GB, Mazzoleni LE, Francesconi CF, Balbinotto G, Mazzoleni F, Wortmann AC, Cardoso Ide Q, Klamt AL, Milbradt TC; Helicobacter Eradication Relief of Dyspetic Symptoms Trial Investigators. Influence of organic and functional dyspepsia on work productivity: the HEROES-DIP study. Value Health. 2011 Jul-Aug;14(5 Suppl 1):S126-9. doi: 10.1016/j.jval.2011.05.021.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Signs and Symptoms, Digestive
- Dyspepsia
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Bacterial Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Protein Synthesis Inhibitors
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Amoxicillin
- Clarithromycin
- Omeprazole
Other Study ID Numbers
- 05-422
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Functional Dyspepsia
-
King Chulalongkorn Memorial HospitalRecruiting
-
Wuhan Central HospitalNot yet recruiting
-
Dong-A ST Co., Ltd.Not yet recruitingFunctional DyspepsiaKorea, Republic of
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Zeria PharmaceuticalRecruitingFunctional DyspepsiaJapan
-
Hong Kong Baptist UniversityXiyuan Hospital of China Academy of Chinese Medical SciencesRecruitingFunctional DyspepsiaHong Kong
-
Seoul National University HospitalCompletedFunctional DyspepsiaKorea, Republic of
-
Wonju Severance Christian HospitalCompletedFunctional DyspepsiaKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.CompletedFunctional DyspepsiaKorea, Republic of
Clinical Trials on Amoxicillin, Clarythromycin, Omeprazole for ten days
-
University Hospital, MontpellierDirection Générale de l'Offre de SoinsNot yet recruitingChild, Only | Community-acquired PneumoniaFrance
-
Dallas VA Medical CenterOtsuka Pharmaceutical Development & Commercialization, Inc.UnknownHelicobacter InfectionUnited States
-
Shandong UniversityZaozhuang Municipal Hospital; Zibo Maternal and Child Health Hospital; Binzhou... and other collaboratorsNot yet recruitingHelicobacter Pylori Infection
-
Helperby Therapeutics LtdRichmond Pharmacology LimitedCompletedAntibiotic Resistant BacteriaUnited Kingdom
-
The Catholic University of KoreaSt Vincent's Hospital; Bucheon St. Mary's HospitalUnknown
-
Assiut UniversityCompleted
-
University of Geneva, SwitzerlandCompletedChronic PeriodontitisSwitzerland
-
Shandong UniversityUnknownHelicobacter Pylori InfectionChina
-
Singapore General HospitalCompletedBleeding Peptic Ulcers DiseaseSingapore
-
Changi General HospitalCompletedBacterial Infection Due to Helicobacter Pylori (H. Pylori)Singapore